...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
【24h】

Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.

机译:非消耗性抗CD4单克隆抗体而非CD28拮抗剂的免疫疗法可保护自发性nod小鼠的胰岛移植免受自身免疫破坏以及同种异体和异种移植排斥。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: T-cell activation and the subsequent induction of effector functions require not only the recognition of antigen peptides bound to MHC molecules by T-cell receptor (TCR) for antigen but also a costimulatory signal provided by antigen presenting cells. CD4 T-cell activation and function require the CD4 molecule as a coreceptor of TCR. The CD28/B7 pathway is a major costimulatory signal for T-cell activation and differentiation. METHODS: The effect of targeting CD4 by nondepleting anti-CD4 monoclonal antibodies (mAbs) versus blocking CD28/B7 by CTLA4Ig, anti-CD80 mAbs, and anti-CD86 mAbs on the prevention of recurrence of autoimmune diabetes after MHC-matched nonobese diabetes-resistant (NOR) islet transplantation in nonobese diabetic (NOD) mice were compared. Whether nondepleting anti-CD4 mAbs prolong allogeneic islet graft survival and xenogeneic pig islet graft survival in diabetic NOD mice were studied. Furthermore, the effect of nondepleting anti-CD4 mAbs combined with CTLA4Ig on allogeneic islet graft survival in NOD mice was investigated. RESULTS: Recurrence of autoimmune diabetes can be prevented by nondepleting anti-CD4 mAbs. Blocking the CD28/B7 costimulatory pathway by CTLA4Ig or by anti-CD80 mAbs and anti-CD86 mAbs cannot prevent recurrence of autoimmune diabetes after islet transplantation. Short-term treatment with nondepleting anti-CD4 mAbs significantly prolongs allogeneic islet graft survival and xenogeneic pig islet graft survival in diabetic NOD mice. But nondepleting anti-CD4 mAbs combined with CTLA4Ig decreased allogeneic islet graft survival. CONCLUSIONS: Nondepleting anti-CD4 mAbs but not CD28 antagonists protect islet grafts in diabetic NOD mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. The efficacy of nondepleting anti-CD4 mAbs is compromised when it combines with CTLA4Ig.
机译:背景:T细胞活化和随后的效应子功能诱导不仅需要识别T细胞受体(TCR)结合抗原的MHC分子的抗原肽,还需要抗原呈递细胞提供的共刺激信号。 CD4 T细胞的活化和功能需要CD4分子作为TCR的共受体。 CD28 / B7途径是T细胞活化和分化的主要共刺激信号。方法:非消耗性抗CD4单克隆抗体(mAbs)靶向CD4相对于CTLA4Ig,抗CD80 mAb和抗CD86 mAb阻断CD28 / B7预防MHC匹配的非肥胖性糖尿病患者自身免疫性糖尿病复发的效果比较了非肥胖糖尿病(NOD)小鼠中的抗性(NOR)胰岛移植。研究了非消耗性抗CD4 mAb在糖尿病性NOD小鼠中是否能延长同种异体胰岛移植物的存活和异种猪胰岛移植物的存活。此外,还研究了非消耗性抗CD4 mAb与CTLA4Ig结合对NOD小鼠同种异体胰岛移植物存活的影响。结果:不消耗抗CD4单抗可预防自身免疫性糖尿病的复发。通过CTLA4Ig或抗CD80 mAb和抗CD86 mAb阻断CD28 / B7共刺激途径不能预防胰岛移植后自身免疫性糖尿病的复发。用非消耗性抗CD4 mAb短期治疗可显着延长糖尿病NOD小鼠的同种异体胰岛移植物存活和异种猪胰岛移植物存活。但是非消耗性抗CD4 mAb结合CTLA4Ig会降低同种异体胰岛移植物的存活率。结论:非消耗性抗CD4 mAb而非CD28拮抗剂可保护糖尿病NOD小鼠的胰岛移植物免受自身免疫破坏以及同种异体和异种移植物排斥。非消耗性抗CD4 mAb与CTLA4Ig结合使用时,其功效会受到损害。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号